Lastly, Capivasertib (AZD5363), an oral AKT inhibitor, has shown promise in phase I trials for PIK3CA‐mutant breast cancer and other solid tumors [40], with ongoing phase II trials like FAKTION (Capivasertib) [41] in breast cancer. This evidence concerns the gene AKT1 and breast cancer.